MeSH term
Frequency | Condition_Probility | Humans | 252 | 0.0 |
Animals | 110 | 0.0 |
DNA-Binding Proteins/*metabolism | 15 | 0.0 |
In Vitro | 6 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
*Milk Proteins | 29 | 6.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Signal Transduction | 46 | 0.0 |
Trans-Activators/*metabolism | 43 | 4.0 |
Mice | 73 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Transgenic | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 175 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 86 | 0.0 |
Signal Transduction/physiology | 10 | 1.0 |
Trans-Activators/*genetics/metabolism | 7 | 6.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Female | 35 | 0.0 |
Interleukin-4/*pharmacology | 37 | 16.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Phosphoproteins/metabolism | 9 | 1.0 |
Phosphorylation | 58 | 0.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Trans-Activation (Genetics) | 9 | 0.0 |
Trans-Activators/genetics/*physiology | 6 | 7.0 |
Transfection | 41 | 0.0 |
Child | 9 | 0.0 |
Child, Preschool | 7 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Genotype | 5 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Male | 26 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Trans-Activators/*genetics | 7 | 2.0 |
B-Lymphocytes/metabolism | 4 | 2.0 |
Immunoglobulin Class Switching/genetics | 2 | 50.0 |
Immunoglobulins, epsilon-Chain/*genetics/metabolism | 2 | 100.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Trans-Activators/genetics/*metabolism | 14 | 3.0 |
Cells, Cultured | 48 | 0.0 |
Down-Regulation | 9 | 0.0 |
Drug Synergism | 10 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Interleukin-4/*antagonists & inhibitors | 3 | 50.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
Receptors, IgE/biosynthesis/genetics | 2 | 100.0 |
Signal Transduction/drug effects | 9 | 1.0 |
Tumor Cells, Cultured | 43 | 0.0 |
Gene Deletion | 2 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Mice, Inbred BALB C | 15 | 0.0 |
Mice, Inbred C57BL | 13 | 0.0 |
Receptors, Interferon/metabolism | 2 | 5.0 |
Receptors, Interleukin-4/metabolism | 6 | 54.0 |
Th1 Cells/cytology/immunology/metabolism | 2 | 25.0 |
Trans-Activators/metabolism | 42 | 4.0 |
Signal Transduction/genetics/*immunology | 8 | 9.0 |
Transcription, Genetic/immunology | 2 | 2.0 |
Up-Regulation/genetics/immunology | 3 | 5.0 |
Variation (Genetics) | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 2 | 1.0 |
B-Lymphocytes/*metabolism | 7 | 3.0 |
Cell Differentiation | 10 | 0.0 |
*Gene Expression Regulation | 7 | 0.0 |
Interleukin-4/pharmacology | 26 | 7.0 |
NF-kappa B/metabolism | 10 | 1.0 |
Signal Transduction/*physiology | 10 | 0.0 |
Trans-Activators/physiology | 9 | 6.0 |
Tyrosine/metabolism | 22 | 1.0 |
Up-Regulation | 8 | 0.0 |
DNA-Binding Proteins/physiology | 7 | 2.0 |
Trans-Activators/*physiology | 11 | 4.0 |
Transcription Factors/physiology | 3 | 1.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
B-Lymphocytes/drug effects/*immunology | 2 | 6.0 |
Gene Expression | 8 | 0.0 |
Interleukin-4/*immunology/pharmacology | 2 | 50.0 |
Mice, Knockout | 14 | 0.0 |
Trans-Activators/immunology | 5 | 35.0 |
Adult | 24 | 0.0 |
Aged | 8 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Chemokines, CC/*metabolism | 2 | 3.0 |
Enzyme Activation | 10 | 0.0 |
Interleukin-13/physiology | 3 | 50.0 |
Interleukin-4/physiology | 5 | 12.0 |
Middle Aged | 11 | 0.0 |
RANTES/metabolism | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Apoptosis/drug effects | 3 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 16 | 1.0 |
Signal Transduction/*drug effects | 8 | 2.0 |
Time Factors | 13 | 0.0 |
Cell Line | 69 | 0.0 |
DNA/metabolism | 12 | 0.0 |
Endothelium, Vascular/cytology/drug effects/metabolism | 2 | 5.0 |
Phosphorylation/drug effects | 9 | 1.0 |
Protein Binding/drug effects | 3 | 0.0 |
*Proto-Oncogene Proteins | 17 | 1.0 |
Trans-Activators/*antagonists & inhibitors | 3 | 23.0 |
Antigens, CD40/*physiology | 2 | 5.0 |
Base Sequence | 43 | 0.0 |
Gene Expression Regulation | 16 | 0.0 |
Molecular Sequence Data | 46 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
Proto-Oncogene Proteins/physiology | 2 | 1.0 |
Disease Models, Animal | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 9 | 0.0 |
Interleukin-2/pharmacology | 5 | 0.0 |
Interleukin-4/genetics/*immunology | 2 | 66.0 |
Rabbits | 2 | 0.0 |
Signal Transduction/*immunology | 4 | 1.0 |
Trans-Activators/*immunology | 2 | 16.0 |
Tyrphostins/pharmacology | 3 | 2.0 |
Binding Sites/genetics | 4 | 0.0 |
Cytokines/metabolism | 3 | 0.0 |
DNA/genetics/metabolism | 3 | 0.0 |
Interleukin-4/*metabolism/pharmacology | 3 | 50.0 |
Oligonucleotide Probes | 2 | 0.0 |
3T3 Cells | 6 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Interleukin-4/metabolism | 11 | 11.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Luciferases/metabolism | 4 | 0.0 |
Precipitin Tests | 8 | 0.0 |
Protein Binding | 20 | 0.0 |
RNA, Messenger/metabolism | 14 | 0.0 |
Recombinant Fusion Proteins/metabolism | 6 | 0.0 |
*Repressor Proteins | 4 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Bronchial Hyperreactivity/immunology/*physiopathology | 2 | 50.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Chemokines, CC/metabolism | 3 | 6.0 |
Chronic Disease | 2 | 0.0 |
Interleukin-13/*metabolism | 4 | 33.0 |
Leukocytes/metabolism | 2 | 1.0 |
Monocyte Chemoattractant Protein-1/metabolism | 2 | 3.0 |
T-Lymphocytes/immunology/metabolism | 2 | 1.0 |
Cell Division | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Interleukin-13/*physiology | 4 | 57.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Interleukin-4/*metabolism | 10 | 26.0 |
Receptors, Interleukin-4/genetics/metabolism | 4 | 44.0 |
Trans-Activators/genetics/metabolism | 3 | 1.0 |
Interleukin-4/antagonists & inhibitors/*physiology | 2 | 100.0 |
Adolescent | 7 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Autocrine Communication | 3 | 4.0 |
Cytokines/biosynthesis/genetics | 4 | 6.0 |
DNA-Binding Proteins/metabolism | 15 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Inflammation | 5 | 1.0 |
Receptors, Interleukin/*physiology | 3 | 12.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Fibroblasts/drug effects/*metabolism | 2 | 4.0 |
Flow Cytometry | 3 | 0.0 |
Interleukin-4/metabolism/pharmacology | 3 | 30.0 |
Receptors, Interleukin-4/genetics/*metabolism | 3 | 60.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Blotting, Western | 9 | 0.0 |
Keratinocytes/*metabolism | 2 | 2.0 |
Kinetics | 5 | 0.0 |
Ligands | 5 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Transcription, Genetic | 15 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 3 | 0.0 |
Amino Acid Sequence | 22 | 0.0 |
Interleukin-4/*physiology | 15 | 32.0 |
Lymphocyte Activation/genetics/*immunology | 2 | 11.0 |
Mutagenesis, Site-Directed | 11 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Signal Transduction/genetics/immunology | 7 | 9.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Trans-Activators/drug effects/metabolism | 2 | 9.0 |
Interleukin-13/pharmacology | 8 | 21.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Immunoglobulin E/biosynthesis/*genetics | 3 | 75.0 |
Interleukins/*pharmacology | 2 | 2.0 |
Promoter Regions (Genetics) | 23 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/metabolism | 6 | 0.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Trans-Activators/chemistry/metabolism/*physiology | 2 | 50.0 |
COS Cells | 7 | 0.0 |
Cercopithecus aethiops | 4 | 0.0 |
Jurkat Cells | 5 | 0.0 |
Receptors, IgE/biosynthesis | 7 | 31.0 |
Binding Sites | 13 | 0.0 |
Comparative Study | 14 | 0.0 |
Genes, Reporter | 7 | 0.0 |
Kidney | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 6 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Receptors, Interleukin-4/*chemistry | 3 | 75.0 |
Trans-Activation (Genetics)/drug effects | 4 | 1.0 |
*Transcription Factors | 4 | 0.0 |
Acetylation | 2 | 0.0 |
Cell Nucleus/metabolism | 9 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
*Trans-Activation (Genetics) | 5 | 0.0 |
Th1 Cells/*physiology | 2 | 11.0 |
DNA-Binding Proteins/analysis | 4 | 5.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
*Signal Transduction | 21 | 1.0 |
Cell Line, Transformed | 11 | 0.0 |
*Chemokines, CC | 3 | 4.0 |
Interleukin-13/*pharmacology | 9 | 20.0 |
Cell Differentiation/genetics/immunology | 2 | 2.0 |
Coculture Techniques | 2 | 0.0 |
Th2 Cells/*cytology/*immunology/metabolism | 2 | 66.0 |
Tyrosine/genetics/metabolism | 2 | 10.0 |
Feedback | 2 | 1.0 |
Th1 Cells/immunology | 2 | 1.0 |
Th2 Cells/immunology | 4 | 2.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Receptors, Interleukin/chemistry/*metabolism | 2 | 22.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
*Germ Cells | 2 | 33.0 |
Immunoglobulin E/*genetics | 6 | 54.0 |
DNA-Binding Proteins/genetics/*metabolism | 8 | 0.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Receptors, IgE/genetics/metabolism | 2 | 50.0 |
Tonsil/cytology | 2 | 2.0 |
Trans-Activators/*genetics/*metabolism | 2 | 5.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Infant, Newborn | 3 | 0.0 |
Promoter Regions (Genetics)/immunology | 4 | 5.0 |
Protein Binding/genetics/immunology | 5 | 6.0 |
Trans-Activators/genetics/metabolism/*physiology | 3 | 11.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
Immunoglobulin E/*biosynthesis | 2 | 4.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Genetic Vectors | 2 | 0.0 |
Interferon Type II/*metabolism | 3 | 4.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Trans-Activators/*biosynthesis/metabolism | 2 | 20.0 |
Antigens, CD40/metabolism | 3 | 4.0 |
Trans-Activators/deficiency/genetics/*physiology | 3 | 20.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
Cytokines/*physiology | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Proto-Oncogene Proteins/genetics/metabolism/*physiology | 2 | 12.0 |
Signal Transduction/genetics | 2 | 0.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 11 | 1.0 |
*Chromosomes, Human, Pair 12 | 3 | 1.0 |
Gene Frequency | 3 | 0.0 |
Hypersensitivity, Immediate/*genetics/immunology | 2 | 50.0 |
*Linkage (Genetics) | 4 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
Response Elements | 2 | 0.0 |
Trans-Activators/chemistry/*metabolism | 4 | 6.0 |
Cattle | 3 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Proteins/metabolism | 6 | 0.0 |
ras Proteins/metabolism | 2 | 1.0 |
Trans-Activators/metabolism/*physiology | 4 | 6.0 |
Transcription, Genetic/*immunology | 2 | 6.0 |
Interleukin-13/metabolism | 4 | 25.0 |
Receptors, IgE/metabolism | 3 | 9.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Alleles | 5 | 0.0 |
Receptors, Cytokine/genetics | 2 | 6.0 |
DNA Primers | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Interferon Type II/physiology | 2 | 2.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
*src Homology Domains | 2 | 1.0 |
Rats | 5 | 0.0 |
Receptors, Interleukin-4/immunology | 3 | 75.0 |
Signal Transduction/immunology | 7 | 2.0 |
Trans-Activators/antagonists & inhibitors/metabolism | 2 | 10.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Transcription, Genetic | 9 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Infant | 4 | 0.0 |
Proteins/analysis | 2 | 1.0 |
Trans-Activators/analysis | 2 | 6.0 |
Asthma/*genetics | 3 | 5.0 |
Japan | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Immunoglobulin E/biosynthesis | 2 | 5.0 |
src Homology Domains | 3 | 0.0 |
Protein-Tyrosine Kinase/*physiology | 4 | 2.0 |
Receptors, Interleukin/physiology | 2 | 13.0 |
Receptors, Interleukin-4/physiology | 4 | 66.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 3 | 1.0 |
DNA-Binding Proteins/genetics/metabolism | 5 | 1.0 |
NF-kappa B/genetics/metabolism | 2 | 3.0 |
Nuclear Proteins/genetics/metabolism | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
*Mutation | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Burkitt Lymphoma | 4 | 4.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Thymidine/metabolism | 2 | 0.0 |
Interleukin-4/*genetics/metabolism | 2 | 66.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Macromolecular Substances | 7 | 0.0 |
Receptors, Interleukin/metabolism | 5 | 8.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Interleukin-4/*antagonists & inhibitors/*physiology | 2 | 100.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Multienzyme Complexes/drug effects/*genetics/metabolism | 2 | 66.0 |
Progesterone Reductase/drug effects/*genetics/metabolism | 2 | 66.0 |
Steroid Isomerases/drug effects/*genetics/metabolism | 2 | 66.0 |
Chemokines, CC/*genetics | 2 | 6.0 |
DNA Primers/genetics | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Gene Expression Regulation/drug effects/*immunology | 3 | 10.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Phosphotyrosine | 2 | 0.0 |
Interleukin-4/biosynthesis/genetics | 2 | 11.0 |
Lymphocyte Count | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
NF-kappa B/metabolism/*physiology | 2 | 13.0 |
Signal Transduction/*genetics/immunology | 2 | 40.0 |
Interleukin-13/antagonists & inhibitors | 3 | 75.0 |
Interleukin-4/antagonists & inhibitors | 3 | 75.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Ribonuclease H, Calf Thymus/metabolism | 2 | 14.0 |
Trans-Activators/biosynthesis/*genetics | 2 | 9.0 |
Interleukin-13/*immunology | 3 | 75.0 |
Interleukin-4/*immunology | 2 | 11.0 |
Receptors, Interleukin-2/immunology | 2 | 3.0 |
Gene Expression Regulation/*immunology | 4 | 3.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Interferon-alpha/*pharmacology | 3 | 2.0 |
Trans-Activators/antagonists & inhibitors/*metabolism | 3 | 13.0 |
Adjuvants, Immunologic/physiology | 3 | 6.0 |
Sequence Analysis | 2 | 0.0 |
Dimerization | 5 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
Interleukin-13/metabolism/*pharmacology | 4 | 66.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
DNA-Binding Proteins/biosynthesis | 2 | 2.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Trans-Activators/biosynthesis | 2 | 5.0 |
Hela Cells | 8 | 0.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Interleukin-4/immunology/*pharmacology | 2 | 25.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Th2 Cells/*immunology | 4 | 3.0 |
Transcription, Genetic/*drug effects | 4 | 1.0 |
Vascular Cell Adhesion Molecule-1/genetics | 2 | 11.0 |
Cell Culture Techniques | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Receptors, Interleukin-4/*genetics | 2 | 8.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
Transcription, Genetic/drug effects/immunology | 2 | 12.0 |
Signal Transduction/drug effects/immunology | 3 | 6.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Models, Biological | 4 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Th2 Cells/metabolism | 2 | 4.0 |
Protein Conformation | 2 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Interleukin-4/metabolism/*pharmacology | 2 | 20.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Electrophoretic Mobility Shift Assay | 5 | 1.0 |
Receptors, Interleukin-4/genetics/*physiology | 2 | 100.0 |
Receptors, Interleukin-4/*physiology | 2 | 66.0 |
Homeostasis | 3 | 0.0 |
Interleukin-13/pharmacology/*physiology | 3 | 42.0 |
Interleukin-4/pharmacology/*physiology | 2 | 33.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Point Mutation | 6 | 0.0 |
Cell Transformation, Viral | 3 | 1.0 |
*Up-Regulation | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Immunoglobulin E/*biosynthesis/blood | 2 | 50.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Species Specificity | 4 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/*immunology | 2 | 4.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Trans-Activators/biosynthesis/genetics/*physiology | 2 | 13.0 |
Alanine | 2 | 2.0 |
Mutagenesis | 2 | 0.0 |
Interferon Type II/biosynthesis | 2 | 0.0 |
Trans-Activators/biosynthesis/*metabolism | 2 | 13.0 |
NF-kappa B/genetics/*metabolism | 2 | 2.0 |
Cricetulus | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 2 | 2.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Phosphotyrosine/metabolism | 3 | 0.0 |
Receptor, Insulin/physiology | 2 | 16.0 |
Sequence Alignment | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Mutation | 3 | 0.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Trans-Activators/drug effects/genetics/*metabolism | 3 | 25.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Antigens, CD40/physiology | 3 | 10.0 |
NF-kappa B/*antagonists & inhibitors | 2 | 4.0 |
Cell Transformation, Neoplastic/genetics/*metabolism | 2 | 7.0 |
Trans-Activators/*chemistry/metabolism | 2 | 13.0 |
Up-Regulation/*immunology | 2 | 3.0 |
Asthma/*genetics/metabolism | 2 | 40.0 |
Genetic Screening | 2 | 0.0 |
Interleukin-4/immunology | 3 | 5.0 |
Receptors, Interleukin-4 | 13 | 19.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Receptors, Interleukin/*metabolism | 3 | 9.0 |
Antigens, CD/metabolism | 3 | 0.0 |
B-Lymphocytes/*immunology/metabolism | 2 | 4.0 |
T-Lymphocytes | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
B-Lymphocytes/cytology/*metabolism | 2 | 8.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 2 | 1.0 |
Trans-Activators/chemistry/*physiology | 2 | 11.0 |
Enzyme Induction | 2 | 0.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Peptides/metabolism | 2 | 0.0 |
Phenotype | 5 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
HT29 Cells | 2 | 1.0 |
Crystallography, X-Ray | 2 | 0.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Amino Acid Motifs | 5 | 0.0 |
Trans-Activators/*genetics/immunology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Bronchi/*cytology | 2 | 13.0 |
Gene Expression/drug effects | 2 | 0.0 |
Antibodies | 2 | 0.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Glycosylation | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Inflammatory Bowel Diseases/*genetics | 2 | 8.0 |
Models, Immunological | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Transcription Factors/*chemistry/metabolism | 2 | 4.0 |
Proline/*analogs & derivatives/pharmacology | 2 | 11.0 |
Thiocarbamates/pharmacology | 2 | 3.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
